Pediatric Haemophilia Activities List (PedHAL) – Parents’ Version
Certified translations for the PedHAL are available in the following languages: Dutch, Flemish, French (Canadian and European), English (UK and USA/Canadian), Danish, Norwegian, Spanish, Portugese, Czech, Bulgarian, Chinese, Japanese, Arabic, Turkish, Swedish, Polish, Korean, Serbian, South African, and Italian. The PedHAL is available free of charge to clinicians and individuals and for a fee to […]
Pediatric Haemophilia Activities List (PedHAL) – Childrens’/Teenagers’ Version
Certified translations for the PedHAL are available in the following languages: Dutch, Flemish, French (Canadian and European), English (UK and USA/Canadian), Danish, Norwegian, Spanish, Portugese, Czech, Bulgarian, Chinese, Japanese, Arabic, Turkish, Swedish, Polish, Korean, Serbian, South African, and Italian. The PedHAL is available free of charge to clinicians and individuals and for a fee to […]
Congenital Fibrinogen Disorders: Clinical features and management
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Philippe de Moerloose disscusses the issues of congenital fibrinogen disorders.
Factor FXIII Deficiency
In the Wednesday morning session on rare and ultra-rare bleeding disorders, Diane Nugent presents work on FXIII deficiency.
Health Technology Assessment: Introduction, American perspective, and European perspective
In the Tuesday afternon session on Health Technology Assessments (HTA), Mark Skinner introduces the topic and then Cliff Goodman and Chris Henshall alternate to present the American and European perspectives, respectively.
The Challenge of Evidence Generation
In the Tuesday morning WFH session on global surveillance and collaboration, Glenn Pierce, explores the challenges of evidence generation.
Essential Medicines List, Orphan Drugs, and Paid Plasma
In the Tuesday morning WFH session on global surveillance and collaboration, Brian O’Mahony, provides his vision for the role of the WFH in ensuring adequate access to a safe supply of hemophilia treatment.
Blood Safety and Donor Deferrals: The history and ongoing risk evaluation
In the Tuesday morning WFH session on global surveillance and collaboration, David Page, discusses donor deferrals, issues of blood safety and the role of the WFH.
Medical Plenary: Hemophilia treatment in 2030
In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.
Ageing with hemophilia: Dental issues
In the Thursday morning session entitled Ageing with Hemophilia: Issues and Challenges Through Different Life Stages, Andrew Brewer presents his experiences working as a dentist with people with hemophilia of all ages. This talk was part of the Panel Discussion session: Ageing with Hemophilia: Issues & challenges through different life stages. See below for other […]
Porcine Factor VIII
In the Monday afternoon session on alternative therapies in the management of inhibitors, Rebecca Kruse-Jarres discusses the latest developments in the use of porcine factor VIII.
Report on the Annual Global Survey 2015
Compiled annually, the Annual Global Survey (AGS) provides demographic and other data on people with hemophilia, von Willebrand disease, other rare factor deficiencies, and inherited platelet disorders throughout the world.